Manager TitleAgeSince
Corporate Secretary 60 08/08/2019
Director TitleAgeSince
Director/Board Member 60 07/06/2019
Director/Board Member 49 21/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+10.00%+5.18%+54.35%+71.20% 60.57B
+1.44%+5.05%+22.52%+99.64% 55.51B
+3.32%+2.31%+11.04%+76.48% 55.22B
+1.53%-4.56%+26.24%+34.23% 43.27B
+7.46%+2.22%+23.44%+94.59% 40.36B
+2.76%+6.16%+242.06%+830.11% 41.63B
-3.79%-7.50%+89.46%+78.72% 33.29B
+5.32%+6.04%+20.27%+52.98% 32.27B
+4.51%+12.37%-40.37%+357.13% 22.91B
Average +3.29%+5.02%+49.89%+188.34% 42.78B
Weighted average by Cap. +3.94%+4.06%+51.99%+172.55%
Logo Nightstar Therapeutics PLC
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company's lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company's third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Employees
-